Objective This article investigates the role of chronic nerve compression in the progression of diabetic peripheral neuropathy (DPN) by gene expression profiling.
Methods Chronic nerve compression was created in streptozotocin (STZ)-induced diabetic rats by wrapping a silicone tube around the sciatic nerve (SCN). Neurological deficits were evaluated using pain threshold test, motor nerve conduction velocity (MNCV), and histopathologic examination. Differentially expressed genes (DGEs) and metabolic processes associated with chronic nerve compression were analyzed.
Results Significant changes in withdrawal threshold and MNCV were observed in diabetic rats 6 weeks after diabetes induction, and in DPN rats 4 weeks after diabetes induction. Histopathologic examination of the SCN in DPN rats presented typical changes of myelin degeneration in DPN. Function analyses of DEGs demonstrated that biological processes related to inflammatory response, extracellular matrix component, and synaptic transmission were upregulated after diabetes induction, and chronic nerve compression further enhanced those changes. While processes related to lipid and glucose metabolism, response to insulin, and apoptosis regulation were inhibited after diabetes induction, chronic nerve compression further enhanced these inhibitions.
Conclusion Our study suggests that additional silicone tube wrapping on the SCN of rat with diabetes closely mimics the course and pathologic findings of human DPN. Further studies are needed to verify the effectiveness of this rat model of DPN and elucidate the roles of the individual genes in the progression of DPN.
Keywords
diabetes -
peripheral neuropathy -
DNA microarray
*Yiji Tu and Zenggan Chen contributed equally to the study and should be the co-first authors.
References
1
Won JC,
Park TS.
Recent advances in diagnostic strategies for diabetic peripheral neuropathy. Endocrinol Metab (Seoul) 2016; 31 (02) 230-238
4
Dahlin LB,
Meiri KF,
McLean WG,
Rydevik B,
Sjöstrand J.
Effects of nerve compression on fast axonal transport in streptozotocin-induced diabetes mellitus. An experimental study in the sciatic nerve of rats. Diabetologia 1986; 29 (03) 181-185
8
Zhang W,
Zhong W,
Yang M,
Shi J,
Guowei L,
Ma Q.
Evaluation of the clinical efficacy of multiple lower-extremity nerve decompression in diabetic peripheral neuropathy. Br J Neurosurg 2013; 27 (06) 795-799
9
Melenhorst WB,
Overgoor ML,
Gonera EG,
Tellier MA,
Houpt P.
Nerve decompression surgery as treatment for peripheral diabetic neuropathy: literature overview and awareness among medical professionals. Ann Plast Surg 2009; 63 (02) 217-221
10
Macaré van Maurik JF,
van Hal M,
van Eijk RP,
Kon M,
Peters EJ.
Value of surgical decompression of compressed nerves in the lower extremity in patients with painful diabetic neuropathy: a randomized controlled trial. Plast Reconstr Surg 2014; 134 (02) 325-332
11
Pande M,
Hur J,
Hong Y.
, et al. Transcriptional profiling of diabetic neuropathy in the BKS db/db mouse: a model of type 2 diabetes. Diabetes 2011; 60 (07) 1981-1989
12
O'Brien PD,
Hur J,
Hayes JM,
Backus C,
Sakowski SA,
Feldman EL.
BTBR ob/ob mice as a novel diabetic neuropathy model: neurological characterization and gene expression analyses. Neurobiol Dis 2015; 73: 348-355
14
Rojewska E,
Korostynski M,
Przewlocki R,
Przewlocka B,
Mika J.
Expression profiling of genes modulated by minocycline in a rat model of neuropathic pain. Mol Pain 2014; 10: 47
16
Herder C,
Brunner EJ,
Rathmann W.
, et al. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care 2009; 32 (03) 421-423
17
Spranger J,
Kroke A,
Möhlig M.
, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52 (03) 812-817
18
Bierhaus A,
Haslbeck KM,
Humpert PM.
, et al. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest 2004; 114 (12) 1741-1751
19
Mu ZP,
Wang YG,
Li CQ.
, et al. Association between tumor necrosis factor-α and diabetic peripheral neuropathy in patients with type 2 diabetes: a meta-analysis. Mol Neurobiol 2017; 54 (02) 983-996
21
Price SA,
Zeef LA,
Wardleworth L,
Hayes A,
Tomlinson DR.
Identification of changes in gene expression in dorsal root ganglia in diabetic neuropathy: correlation with functional deficits. J Neuropathol Exp Neurol 2006; 65 (07) 722-732
22
Lee SW,
Song KE,
Shin DS.
, et al. Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes. Diabetes Res Clin Pract 2005; 69 (02) 175-179
25
Neidhardt J,
Fehr S,
Kutsche M,
Löhler J,
Schachner M.
Tenascin-N: characterization of a novel member of the tenascin family that mediates neurite repulsion from hippocampal explants. Mol Cell Neurosci 2003; 23 (02) 193-209
26
Vincent AM,
Hayes JM,
McLean LL,
Vivekanandan-Giri A,
Pennathur S,
Feldman EL.
Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes 2009; 58 (10) 2376-2385
27
Hur J,
Sullivan KA,
Pande M.
, et al. The identification of gene expression profiles associated with progression of human diabetic neuropathy. Brain 2011; 134 (Pt 11): 3222-3235
28
Luo L,
Zhou WH,
Cai JJ.
, et al. Gene expression profiling identifies downregulation of the neurotrophin-MAPK signaling pathway in female diabetic peripheral neuropathy patients. J Diabetes Res 2017; 2017: 8103904